Mangiferin attenuates DSS colitis in mice: Molecular docking and in vivo approach

Research paper by Sahil Somani, Shitalkumar Zambad, Ketan Modi

Indexed on: 27 Apr '16Published on: 26 Apr '16Published in: Chemico-Biological Interactions


Inflammation, oxidative stress and altered mucosal barrier permeability are potential etiopathological or triggering factors for inflammatory bowel disease (IBD). In this study, the therapeutic potential of Mangiferin was investigated in vivo in mouse model of colitis and also attempts were made to understand mechanistic insights of Mangiferin in IBD. In present study, colitis was induced by administration of 5% DSS for 11 days, followed by 3 days of DSS free period. On day 14, animals were sacrificed and colon tissues were taken for biochemical and histological analysis. Therapeutic treatment with Mangiferin after colitis induction (i.e. day 5) ameliorated symptoms of colitis (presence of blood in stools, body weight loss and diarrhea) as evidenced by reduced DAI score, attenuated the levels of catalase (CAT), reduced glutathione (GSH), superoxide dismutase (SOD), malondialdehyde (MDA), myeloperoxidase (MPO). It also decreased the colonic pro-inflammatory mediators tumor necrosis factor (TNF-α), interleukin 1β (IL-1β) levels, matrix metalloproteinase-9 (MMP-9) activity and histopathological score. Molecular docking of Mangiferin against TNF-α and MMP-9 was evaluated using GLIDE software. Mangiferin demonstrated the glide score of −8.04 kcal/mol for TNF-α and −9.97 kcal/mol for MMP-9, which indicated its binding potential with TNF-α and MMP-9. In conclusion, Mangiferin reduces colonic damage in a murine model of colitis, alleviates the oxidative and inflammatory events partly through directly influencing the activity of TNF-α and MMP-9 and therefore might have therapeutic usefulness in the management of inflammatory bowel disease.

Figure 10.1016/j.cbi.2016.04.033.0.jpg
Figure 10.1016/j.cbi.2016.04.033.1.jpg
Figure 10.1016/j.cbi.2016.04.033.2.jpg
Figure 10.1016/j.cbi.2016.04.033.3.jpg
Figure 10.1016/j.cbi.2016.04.033.4.jpg
Figure 10.1016/j.cbi.2016.04.033.5.jpg
Figure 10.1016/j.cbi.2016.04.033.6.jpg